|
🇺🇸 FDA - Updated information on recommended AI for NDSRIs (23/Feb/2024) - Tables 2 & 3
|
|
14
|
1398
|
February 27, 2024
|
|
Anybody using Thermal Energy Analysis for Nitrosamine testing?
|
|
6
|
806
|
February 27, 2024
|
|
AI value for Nitroso Folic acid
|
|
4
|
1390
|
February 26, 2024
|
|
GC-ECD as a method of detection for nitrosamines
|
|
0
|
134
|
February 26, 2024
|
|
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study Using the Software Program Zeneth
|
|
3
|
260
|
February 24, 2024
|
|
Mechanochemistry: Solid phase nitrosation for reference standards synthesis and impurity investigations?
|
|
1
|
233
|
February 21, 2024
|
|
HESI Open call to Q(SAR) and QM working group
|
|
3
|
504
|
February 20, 2024
|
|
Method of Analysis for N nitroso Diclofenac and Quetiapine
|
|
8
|
639
|
February 20, 2024
|
|
AI for en Indole struktur (N-Nitroso melatonin)
|
|
8
|
1135
|
February 20, 2024
|
|
CDER Drug Safety Priorities Fiscal Year 2023
|
|
1
|
356
|
February 16, 2024
|
|
Risk characterization of N-nitrosodimethylamine in pharmaceuticals -Pub
|
|
6
|
544
|
February 16, 2024
|
|
New Validated LC-MS Method Development and Estimation of Nitrosamine impurities in Canaglifozin -Pub
|
|
0
|
337
|
February 16, 2024
|
|
Testig method for nitroso Ciprofloxacin
|
|
12
|
968
|
February 16, 2024
|
|
NDSRIs standards (for confirmatory testing or ames/other tests)
|
|
15
|
1199
|
February 14, 2024
|
|
Discussion on Cleaning Validation Requirements for Nitrosamines
|
|
2
|
322
|
February 14, 2024
|
|
Developing and validating read-across workflows that enable decision making for toxicity and potency: Case studies with N-nitrosamines -Pub
|
|
4
|
358
|
February 14, 2024
|
|
Nitrosamines Severity (impact) - a quantitative model proposal?
|
|
3
|
748
|
February 12, 2024
|
|
Analytical Challenge for detecting NDSRI in Ritonavir Tablets
|
|
8
|
273
|
February 12, 2024
|
|
New ICH Guideline Q14
|
|
0
|
320
|
February 12, 2024
|
|
Nitrosamine requirements for probiotics
|
|
4
|
178
|
February 12, 2024
|
|
TALK SERIES: Navigating Nitrosamine and NDSRIs regulations with Dr. Reddy´s Laboratories
|
|
1
|
572
|
February 11, 2024
|
|
Defining nitrosamine acceptable intake based on technical feasibible limit rather than CPCA
|
|
6
|
301
|
February 11, 2024
|
|
Skipping risk assessment
|
|
4
|
305
|
February 11, 2024
|
|
Top 10 deficiencies observed in new CEP applications for chemical purity assessed in 2023
|
|
1
|
454
|
February 9, 2024
|
|
In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products -Pub
|
|
0
|
406
|
February 8, 2024
|
|
🗃 Poll: Interest of having a commercial directory here in the community?
|
|
13
|
974
|
February 8, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
244
|
February 8, 2024
|
|
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's
|
|
5
|
462
|
February 7, 2024
|
|
Notifying FDA of a Discontinuance or Interruption in Manufacturing
|
|
0
|
166
|
February 7, 2024
|
|
TGA (Australia) :australia: Updates Published Acceptable Intakes
|
|
3
|
540
|
February 7, 2024
|